Technology
Health
Biotechnology

NantKwest

$1.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.79%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell NantKwest and other stocks, options, ETFs, and crypto commission-free!

About NK

NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. Read More The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.

Employees
161
Headquarters
San Diego, California
Founded
2002
Market Cap
125.32M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
253.79K
High Today
$1.29
Low Today
$1.20
Open Price
$1.29
Volume
106.73K
52 Week High
$4.23
52 Week Low
$0.93

Collections

Technology
Health
Biotechnology
Cancer Prevention
2015 IPO
US
North America

NK Earnings

-$0.37
-$0.32
-$0.27
-$0.22
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 5, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.